NCT00222612View on ClinicalTrials.gov

Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003

PHASE4UnknownINTERVENTIONAL
Enrollment

2,100

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Acute Lymphoblastic Leukemia
Interventions
OTHER

Reduced intensification

Deletion of one 7 week treatment block containing dexamethasone, vincristine, doxorubicin, Peg-asparaginase, intrathecal methotrexate, cyclophosphamide, cytarabine.

DRUG

Standard childhood UK ALL protocol

No additional treatment to standard protocol.

DRUG

Intensified treatment including Capizzi maintenance

Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase

Trial Locations (1)

S10 2TH

RECRUITING

Sheffield Children's Hospital, Sheffield

Sponsors

Collaborators (1)

Medical Research Council
All Listed Sponsors
collaborator

Medical Research Council

OTHER_GOV

lead

University of Oxford

OTHER

NCT00222612 - Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 | Biotech Hunter | Biotech Hunter